BIOSURE™ HEALICOIL™ PK Bone In-growth Study
A Radiographic Study of Patients Treated With the BIOSURE™ HEALICOIL™ PK Interference Screw for ACL Repair With Soft Tissue Fixation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ACL tear requiring surgical reconstruction with semitendinosus/gracilis graft.
- Willing and able to give voluntary informed consent to participate in this study
- Willing and able, in the opinion of the investigator, to cooperate with study procedures and willing to return to study site for all post-operative study visits.
- Subject is between 18 and 50 years at the time of surgery
- ASA group 0-2 (limited medical illness).
Exclusion Criteria:
- Revision ACL reconstruction
- Cartilage injury (IKDC Grade IV lesion> 2 cm2)
- Current malignant disease
- Rheumatoid arthritis
- Osteonecrosis or Avascular Necrosis
- Ankylosing spondylitis
- Subject is Obese; BMI > 35
- Subject is pregnant or plans to become pregnant during the study
- Subject has received medical treatment within 6 weeks of enrollment with any of the following:
Glucocorticoids Growth hormone
- Participating in another investigational trial or on-going study that would interfere with the assessment of the primary and secondary outcomes
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observational
BIOSURE™ HEALICOIL™ PK Interference Screw
|
Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone In-growth measured by CT scans
Time Frame: 1 year
|
Bone In-growth measured by CT scans
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bone In-growth measured by CT scans
Time Frame: 6 months
|
Bone In-growth measured by CT scans
|
6 months
|
|
Improvement in IKDC Knee Examination scoring from baseline to 1 year post-operatively
Time Frame: 1 year
|
1 year
|
|
|
Improvement in the IKDC Subjective Knee Evaluation scoring from baseline to 1 year post-operatively
Time Frame: 1 year
|
1 year
|
|
|
Improvement in IKDC Knee Examination scoring from baseline to 2 years post-operatively
Time Frame: 2 years
|
2 years
|
|
|
Improvement in the IKDC Subjective Knee Evaluation scoring from baseline to 2 years post-operatively
Time Frame: 2 Years
|
2 Years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Martin Lind, MD, PhD, Aarhus University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 15000946
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.